Navigating next-generation HR+/HER2- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression.

Neven, Patrick; Dullens, Lieke; Han, Sileny; Deblander, Anne; Van Herck, Yannick; Van Houdt, Maxime; Wildiers, Hans

Navigating next-generation HR⁺/HER2^- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression.

Neven, Patrick; Dullens, Lieke; Han, Sileny; Deblander, Anne; Van Herck, Yannick; Van Houdt, Maxime; Wildiers, Hans.

Afiliação

Neven P; Department of Oncology, KU Leuven-University of Leuven, Leuven, Belgium.
Dullens L; Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium.
Han S; Master Student of Medicine, KU Leuven-University of Leuven, Leuven, Belgium.
Deblander A; Department of Oncology, KU Leuven-University of Leuven, Leuven, Belgium.
Van Herck Y; Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium.
Van Houdt M; Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium.
Wildiers H; Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven, Belgium.

Transl Breast Cancer Res ; 4: 31, 2023.

Article em En | MEDLINE | ID: mdl-38751459

Palavras-chave

Metastatic breast cancer (MBC); abemaciclib; cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i); hormone receptor-positive (HR+); tucidinostat

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Breast Cancer Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google